In this section...
The annual changes to the WADA prohibited list will come into operation on January 1 2008.
The good news is there are no major changes this year and nothing that should affect the vast majority of Scottish Institute Athletes.
The changes include:
There are fine print changes in the anabolic steroid category including comments on T/E ratio.
SARMs (Selective Androgen Receptor Modulators) used in muscle wasting disease and androgen replacement therapy are included in the anabolic category (S1)
Some fine pint changes in S2 to make sure all insulins are covered.
In S4 agents that modify myostatin function have been added to S4.
The chemical and physical manipulation section M2 has had a wording change, “Intravenous infusions prohibited. In an acute medical situation where the method is deemed necessary a retroactive therapeutic use exemption will be required”.
No athlete needs worry about receiving an infusion in hospital but it might be wise to get the doctor to sign a therapeutic use exemption certificate (available on the Institute website). It might be more of a problem where clinic treatment involves an intra venous drip and this must be discussed before proceeding and may end up controversially.
In the specific substances Clenbuterol is listed in the S1.2 section as other anabolic agent. Clenbuterol is a Beta-2-agonist which may be used to treat asthma but is not ordinarily prescribed In UK.
Alpha reductase inhibitors e.g. Finasteride, is now considered specific substances. These drugs can be used as masking agents for androgenic steroids though there are now testing methods that can detect if it is being used as masking agents. Finasteride is in common use as a baldness cure so beware.
Fortunately most of these changes will not impact on many people.
DR BRIAN WALKER
MB ChB MD FFSEM Dip Sp Med (SRC)
Head of Sports Medicine
The changes include:
There are fine print changes in the anabolic steroid category including comments on T/E ratio.
SARMs (Selective Androgen Receptor Modulators) used in muscle wasting disease and androgen replacement therapy are included in the anabolic category (S1)
Some fine pint changes in S2 to make sure all insulins are covered.
In S4 agents that modify myostatin function have been added to S4.
The chemical and physical manipulation section M2 has had a wording change, “Intravenous infusions prohibited. In an acute medical situation where the method is deemed necessary a retroactive therapeutic use exemption will be required”.
No athlete needs worry about receiving an infusion in hospital but it might be wise to get the doctor to sign a therapeutic use exemption certificate (available on the Institute website). It might be more of a problem where clinic treatment involves an intra venous drip and this must be discussed before proceeding and may end up controversially.
In the specific substances Clenbuterol is listed in the S1.2 section as other anabolic agent. Clenbuterol is a Beta-2-agonist which may be used to treat asthma but is not ordinarily prescribed In UK.
Alpha reductase inhibitors e.g. Finasteride, is now considered specific substances. These drugs can be used as masking agents for androgenic steroids though there are now testing methods that can detect if it is being used as masking agents. Finasteride is in common use as a baldness cure so beware.
Fortunately most of these changes will not impact on many people.
DR BRIAN WALKER
MB ChB MD FFSEM Dip Sp Med (SRC)
Head of Sports Medicine
